NIQ Form 4: 19,097 RSUs awarded to director Elizabeth Lempres
Rhea-AI Filing Summary
Elizabeth Cahill Lempres, a director of NIQ Global Intelligence plc (NIQ), was granted 19,097 restricted share units (RSUs) on 08/20/2025. Each RSU represents a contingent right to receive one ordinary share and the award was recorded at a price of $0. After the grant the reporting person beneficially owns 19,097 ordinary shares directly. The RSUs vest in four equal installments of 25% on each of the four anniversaries of the vesting commencement date of 08/20/2025.
The Form 4 was filed as a single reporting person filing and signed on behalf of the reporting person by an attorney-in-fact on 08/22/2025.
Positive
- Director awarded equity (19,097 RSUs) which aligns the reporting person's interests with shareholders through time-based vesting
- Clear vesting schedule provided: 25% on each of four anniversaries starting 08/20/2025
Negative
- None.
Insights
TL;DR: Routine director equity grant disclosed; aligns director incentives with shareholders but is a standard compensation event.
The filing documents a standard equity-based compensation award to a director: 19,097 RSUs vesting 25% annually over four years. This is a typical mechanism to align a director's interests with shareholders by converting future service into equity. The disclosure is complete for Form 4 purposes, specifying grant size, vesting schedule, and beneficial ownership following the grant. No additional corporate governance actions, forfeiture terms, or performance conditions are disclosed in this form.
TL;DR: The grant is a non-cash RSU award; materiality depends on context not provided in this filing.
The document shows an award of 19,097 RSUs at $0 price, each convertible to one ordinary share upon vesting. The vesting schedule is time-based: 25% on each of the four anniversaries beginning 08/20/2025. The Form 4 discloses post-transaction beneficial ownership as 19,097 shares direct. The filing does not provide grant fair value, linkage to pay philosophy, or percentage of outstanding shares, so assessment of compensation competitiveness or dilution impact cannot be made from this form alone.